Skip to main content


Texas Medical Center

Blood Disorders, Cancer, Adult Hematology-Oncology
Phone: 832-822-4208
Fax: 832-825-1503


6701 Fannin St., Ste. 1510.11
Houston, TX 77030

Research Laboratory

Research Area

Kenneth L. McClain, MD, PhD

Director, Histiocytosis Program
Director, Pediatric Lymphoma-Histiocytosis Fellowship Program
Professor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine


School Education Degree Year
University of Minnesota Medical School at Minneapolis fellowship Hematology-Oncology 1981
National Institutes of Health fellowship Molecular & Human Genetics 1979
Johns Hopkins University School of Medicine residency Pediatrics 1976
Johns Hopkins University School of Medicine internship Pediatrics 1974
University of Chicago, Pritzker School of Medicine medical school Doctor of Medicine 1973
University of Chicago, Pritzker School of Medicine university Doctor of Philosophy 1972


Dr. Kenneth McClain is Director of the Histiocytosis Program at Texas Children’s Cancer and Hematology Centers and a member of the leukemia and lymphoma programs. Dr. McClain and Dr. Carl Allen see 100 newly-diagnosed patients with a variety of histiocytic diseases each year. His clinical interests include: hematologic disorders, leukemia, lymphoma, histiocytosis, and sickle cell disease.

Board Certifications American Board of Pediatrics - Pediatrics and Pediatric Hematology/Oncology


Organization Name Role
American Society of Hematology (ASH) Member
American Society of Pediatric Hematology/Oncology (ASPHO) Member
Current Reviews in Pediatrics Editorial Board, 2004-Present
Gulf Coast Hematology Society (GCHS) Past-President
Histiocyte Society Past-President
Histiocytosis Association of America (HAA) Board Member
PDQ Pediatric Treatment Editorial Board 2006 - Present
Society for Pediatric Research Member, 1986-Present

Research Statement

Dr. Kenneth McClain's research is focused on the clinical and biologic aspects of Langerhans cell histiocytosis (LCH). He is a key member of the clinical trials group of the Histiocyte Society. A number of clinical studies are in progress or development including new therapeutic interventions for CNS LCH. Current biologic studies in his lab are focused on determining the gene expression profiles Langerhans cells and lymphocytes from control and patient tissues and making clinical correlations.

Research Interests Clinical and biologic aspects of Langerhans cell histiocytosis (LCH) Gene expression profiles


2019: George R. Buchanan Lectureship Award, American Society of Pediatric Hematology/Oncology 2009: Who's Who 2005-2009: Texas Super Doctor 2003-2009: Best Doctor 2007: Nesbit Prize for Best Clinical Paper. 23rd Annual Histiocyte Society Meeting, Cambridge England 2005-2006: Texas Super Doctor 2004: Montclair Who’s Who in Healthcare 2003-2008: Best Doctors in America 2002: Visiting Professor of Pediatrics. McGill University.  2002: Ph.D. Thesis Opponent. The Karolinska Institute, Stockholm Sweden 2000-2003: President, Histiocyte Society 2000: Who’s Who 1996: Visiting Professor of Pediatrics, Charles University, Second Medical Faculty, Motol, Prague, Czech Republic, Conferred 1998-2001: Editorial Board, Medical and Pediatric Oncology

AcademicKeys Who’s Who in Medical Sciences



Latest Videos

Shauntelle’s Story: Traveling Across the Globe for Histiocytosis Treatment at Texas Children’s

Histiocytosis: A Comprehensive Overview with Texas Children’s Cancer Center

Q&A: What is histiocytosis?

* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.